Dr. James is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3855 Health Sciences Dr # 820
Ucsd Moore's Cancer Center
La Jolla, CA 92093Phone+1 858-822-7894Fax+1 858-534-5620
Education & Training
University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008- University of California (San Diego) Medical CenterResidency, Internal Medicine, 2002 - 2005
Pennsylvania State University College of MedicineClass of 2002
Certifications & Licensure
CA State Medical License 2004 - 2025
Clinical Trials
- Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2008 Feb 01
- Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2010 Aug 01
- Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2010 Aug 01
Publications & Presentations
PubMed
- 1198 citationsIbrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.John C. Byrd, Jennifer R. Brown, Susan O'Brien, Jacqueline C. Barrientos, Neil E. Kay
The New England Journal of Medicine. 2014-07-11 - 874 citationsResistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor IbrutinibJennifer A. Woyach, Richard R. Furman, Ta-Ming Liu, Hatice Gulcin Ozer, Marc Zapatka
The New England Journal of Medicine. 2014-06-11 - 69 citationsIbrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study.Margaret A. Tempero, D-Y. Oh, J. Tabernero, Michele Reni, E. Van Cutsem
Annals of Oncology. 2021-02-01
Press Mentions
Results from IMBRUVICA® (Ibrutinib) RESONATE-2 Study Provide up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL)June 4th, 2021- “Collaboration Is Key.” with Danelle JamesDecember 9th, 2020
AbbVie Submits Supplemental New Drug Application to U.S. FDA for IMBRUVICA® (Ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic LeukemiaDecember 23rd, 2019- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
